anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The study sample constituted patients diagnosed with DDWoR with limited opening according to the Turkish version of the Diagnostic Criteria for Temporomandibular Disorders (DC/TMD Axis 1 questionnaire and examination form). The included patients with DDWoR-induced complaints persisting for more than three months were considered chronic (Group 1), and those with a shorter duration were considered acute (Group 2). For clinical diagnosis of DDWoR, Significant limitation of mouth opening, less than 35 mm assisted mouth opening, less than 4 mm increase in mouth opening with passive stretching, less than 7 mm contralateral movement of the mandible, and deviation of the mandible to the affected side during mouth opening was considered sufficient. The DC/TMD questionnaire and clinical examination diagnoses were confirmed by magnetic resonance images (MRI).

Preoperative and postoperative clinical examinations consisted of recording demographic information, amount of maximum mouth opening (MMO), and determination of McGill Pain Questionnaire (MPQ) and Visual Analog Scale (VAS) scores. MMO values were determined as the distance between the incisal edges of upper and lower central teeth and recorded in millimeters. MPQ scores were obtained with the questionnaire form consisting of four subsections. In the first subsection of the questionnaire, besides the patient's demographic data, the location of the current pain and whether it comes from superficial or deep tissues are questioned. In the second subsection, there are 20-word groups containing 78 words that ask the Sensory (groups 1-10), Affective (groups 11-15), Evaluative (group 16), and Miscellaneous (groups 17-20) components of current pain. In the third subsection, the relationship of pain with time is questioned. There are word groups to determine the continuity of pain, its frequency, and factors that increase or reduce pain. In the fourth subsection, five-word groups ranging from "mild" pain to "unbearable" pain to determine the severity of the pain; There are also six questions to assess the severity of pain that the patient can accept or experience without discomfort, which is also defined as "experienceable=target pain." The obtainable MPQ scores range from 0 to 78. The higher the scores, the greater the pain. Also, preoperative and postoperative VAS scores were obtained by marking a point on a 10 cm line. The score was calculated as the distance in centimeters between the zero and the marked points.
The study was designed as a prospective randomized trial and was performed in three stages. In the first stage, primary hypertension was diagnosed and antihypertensive monotherapy was implemented. In the second stage, patients underwent antihypertensive monotherapy lasting three months. The subjects received diuretics; calcium antagonists (Ca-antagonists); angiotensin-converting-enzyme inhibitors (ACE-Is); angiotensin II receptor antagonists (ARBs); or β-blockers. After three months of monotherapy, patients were divided using a randomization list into three equal groups: C (control group), D (diet group) and S (supplementation group). In the third stage, which lasted 30 days, subjects from all groups received the same antihypertensive drug as in the second stage and either an optimal-mineral-content diet (group D), zinc supplementation (group S), or continued drug use with no change in diet and no mineral supplementation (group C). Patients from group D received an optimal-mineral-content properly balanced diet enriched in food with high zinc content prepared individually for each patient by a qualified dietician. Patients from group S received zinc supplementation as one capsule containing 15 mg of Zn taken orally once a day in the morning, two hours after antihypertensive drug administration with no change in diet, through all 30 days of the third stage of the trial.

During the study, patients were asked to not use dietary supplements and not to change their lifestyle or level of physical activity. On the last day of each stage of the study, blood, urine, and hair samples were collected from the subjects, and blood pressure and anthropometric parameters were measured.
This study is designed determine progression free survival (PFS) of nab-paclitaxel administered in combination with gemcitabine at two different dose combinations in patients with unresectable stage IIIB/stage IV non-squamous non-small cell lung cancer (NSCLC). Two dosing strategies of the nab-paclitaxel plus gemcitabine combination will be compared for efficacy and tolerability. One arm will combine both agents at their current Food and Drug Administration (FDA) approved doses for the indication of non-small cell lung cancer (NSCLC). This arm will utilize gemcitabine 1250 mg/m2 IV day 1 and day 8 (FDA approved dose in combination with cisplatin) combined with nab-paclitaxel 100 mg/m2 IV day 1, 8 and 15 every 21 days (FDA approved dose in combination with carboplatin). The second arm will utilize the drugs at doses that are approved by the FDA when combined with one another in metastatic pancreatic adenocarcinoma. This arm will consist of gemcitabine 1000 mg/m2 IV day 1, 8 and 15 combined with nab-paclitaxel at 125 mg/m2 IV day 1, 8 and 15 every 28 days. Patients will be randomized equally to the two treatment arms. Primary objective is to assess progression-free survival (PFS). Toxicity assessment, response and overall survival are secondary endpoints. Statistical power is based on the comparison to historical control within each treatment arm. In particular, a sample size of 23 patients in each arm will have 84% power to differentiate the 3-month PFS of 30% (null hypothesis) versus 60% (alternative) based on a 2-sided test at a significance level of 0.05. There will be a lead-in phase to this trial for each treatment arm with a cohort size of 3 and a maximum of 6 patients.
Oral transmucosal fentanyl citrate lozenge is a solid formulation of fentanyl, an opioid agonist, intended for oral transmucosal administration. Oral transmucosal fentanyl citrate is formulated as a white to off-white solid drug matrix on a handle that is fracture resistant (ABS plastic) under normal conditions when used as directed.

Oral transmucosal fentanyl citrate is designed to be dissolved slowly in the mouth to facilitate transmucosal absorption. The handle allows the oral transmucosal fentanyl citrate unit to be removed from the mouth if signs of excessive opioid effects appear during administration.

Active Ingredient: Fentanyl citrate USP is N-(1-Phenethyl-4-piperidyl) propionanilide citrate (1:1). Fentanyl is a highly lipophilic compound (octanol-water partition coefficient at pH 7.4 is 816:1) that is freely soluble in organic solvents and sparingly soluble in water (1:40). The molecular weight of the free base is 336.5 (the citrate salt is 528.6). The pKa of the tertiary nitrogens are 7.3 and 8.4. The compound has the following structural formula:

Inactive Ingredients: Raspberry flavor, citric acid, confectioners sugar, dextrates, magnesium stearate, dibasic sodium phosphate, modified food starch, ethanol, water, purified shellac, propylene glycol, FD&C blue no. 1, ammonium hydroxide.
Pain is a common co-morbidity for HIV-infected patients. Prevalence studies suggest that, on average, half of all HIV-infected persons suffer pain. Chronic pain can lead to heavy alcohol use among HIV-infected persons, which may in turn be a barrier to treatment/control of HIV and contribute to spread of HIV. Thus there is an urgent need to address pain among persons with HIV. Opioid receptor antagonists such as naltrexone and nalmefene, which are licensed for treatment of alcohol use disorders, show promise as being effective and safe treatments for chronic pain among persons with HIV. This study will pilot test novel pharmacotherapies (opioid receptor antagonists) to improve chronic pain among HIV-infected heavy drinkers. The specific aims of the research is to assess the feasibility, tolerability and safety of using opioid receptor antagonists (low-dose naltrexone and nalmefene) to treat pain among HIV-infected persons with heavy alcohol use and chronic pain.
Intravaginal ring 55.0 mm in diameter, consisting of two segments of polyurethane tubing with an outer diameter of 5.5 mm containing no active experimental ingredients. Used for one month. Used for 90 days (continuous).
The present invention provides a blackberry lily total flavonoid extract and a preparation method thereof. The extract is obtained from blackberry lily or iris. The content of total flavonoid is from 55 to 90%, wherein iridin is contained, and the extract is selected from one or a plurality of kinds of irigenin, wild iridin, wild iris flavin and minor wild iris flavin. The content of the iridin is from 10 to 50%. The preparation process of macroporous resin has the advantages of simpleness, convenience and good reproducibility, and flavonoid components are effectively enriched. Non-flavonoid components such as triterpenoids of iris aldehyde, etc., steroids, etc. are removed. The preparation process of macroporous resin also has the advantages of easy control of finished products, high content, high extraction efficiency, industrial production, etc. The present invention also provides a medical composition comprising the blackberry lily total flavonoid extract. The blackberry lily total flavonoids extract has good anti-osteoporosis function, anti-inflammatory function, anti-myocardial ischemia function and anti-cerebral ischemia function and can be widely used for curing and/or preventing osteoporosis, various inflammation and cardio-cerebrovascular diseases.
Suboccipital inhibitory pressure technique. According to this technique, the suboccipital musculature is palpated until contact is made with the posterior arch of the atlas, and progressive and deep gliding pressure is applied, pushing the atlas anteriorly. The occiput rests on the hands while the atlas is supported by the fingertips. Finger pressure must be maintained for 10 minutes to produce the therapeutic effect of inhibiting the suboccipital soft tissues.
INTRODUCTION: Ventilator associated pneumonia (VAP) leads to an increase in morbidity, mortality, and healthcare costs. In addition to increased evidence from the latest European and American guidelines (published in 2017 and 2022, respectively), in the last two years, several important clinical experiences have added new prevention tools to be included to improve the management of VAP.
AREAS COVERED: This paper is a narrative review of new evidence on VAP prevention. We divided VAP prevention measures into pharmacological, non-pharmacological, and ventilator care bundles.
EXPERT OPINION: Most of the effective strategies that have been shown to decrease the incidence of complications are easy to implement and inexpensive. The implementation of care bundles, accompanied by educational measures and a multidisciplinary team should be part of optimal management. In addition to ventilator care bundles for the prevention of VAP, it could possibly be beneficial to use ventilator care bundles for the prevention of noninfectious ventilator associated events.
PURPOSE: Participants in the 100,000 Genomes Project, a clinical/research initiative delivered through the UK National Health Service, were offered screening for "additional findings" (AFs): pathogenic/likely pathogenic secondary findings in genes associated with familial hypercholesterolemia or a cancer predisposition syndrome. Understanding the psychological and behavioral responses to secondary findings can inform the clinical utility of a search and disclose policy.
METHODS: Thirty-two adult AF recipients took part in semi-structured interviews analyzed using deductive and inductive thematic analysis.
RESULTS: Five themes were constructed: cognitive responses to an AF, emotional and psychological responses, personal control, perceived risk of AF-associated disease, and family implications. Many participants had misunderstood or incompletely remembered consent for AFs, and most were surprised or shocked to receive an AF. Although many ultimately appreciated knowing about the risk conferred, some struggled to make sense of their disease risk, which complicated decision making about risk management, particularly for women with a BRCA AF. Recipients sought control through seeking clinical evaluation and information, and informing relatives. Difficulties with conceptualizing risk and lack of AF-associated disease family history meant that some hesitated to inform relatives.
CONCLUSION: Genome sequencing programs offering secondary findings require attention to consent processes. Post-disclosure care should aim to promote recipients' perceived personal control.
PURPOSE: To obtain a new polypeptide having a specific amino acid sequence, useful for e.g. treating neuroglioma and lung cancer, by immobilizing a human s-Myc-like gene following its isolation from a human placenta genome DNA by e.g. PCR process followed by manifesting the gene. CONSTITUTION: This new polypeptide has an amino acid sequence containing an amino acid sequence expressed by the formula, being effective for treating tumors, esp. neuroglioma and lung cancer, thus useful for e.g. drug's for tumor therapy. When a recombinant vector containing a gene DNA coding for this polypeptide is embedded in liposome and administered into neuroglial cells, suppression or apoptosis of oncocytes can be induced. The other objective is derivatives from this new polypeptide, including one having human s-Myc-like polypeptide activity where at least one amino acid in the original polypeptide has been substituted, deleted or transfected. This new polypeptide is obtained by immobilizing a human s-Myc-like gene following its isolation from a human placenta genome DNA by e.g. PCR process followed by transfecting this gene into a manifestation vector to effect manifestation.
BACKGROUND: Surgical approach in the treatment of thymoma is varied. This retrospective study aimed to evaluate the outcomes of different surgical approaches in the treatment of thymoma.
METHODS: From January 2020 to December 2023, a total of 208 patients underwent thoracoscopic surgical treatment and were diagnosed with thymoma by postoperative pathological result in our institution. We collected and then analysed potential factors including general conditions, surgical approaches, preoperative clinical symptoms, surgical procedures, postoperative hospital stay, postoperative drainge, postoperative pain score, postoperative complications and postoperative follow-up.
RESULTS: Of the 208 patients, 98 patients underwent surgery via subxiphoid approach (47.1%) and 110 patients via lateral intercostal approach (52.8%). The duration of the surgical procedure (P = 0.02), intraoperative blood loss (P = 0.045), total postoperative drainage (P = 0.021), postoperative drainage per day (P = 0.004) and Postoperative pain score (Day1 P = 0.010 and Day2 P = 0.002)showed a significant difference between these two groups. 31 patients (14.9%) received postoperative radiotherapy. One patient died due to postoperative radiotherapy. No recurrence occurred in one-year follow-up.
CONCLUSIONS: The present study not only showed that subxiphoid approach was a safe and feasible technique for thymoma, with a potentially faster postoperative recovery and less postoperative pain.
System and methods to allow for communication, decoding, interpretation and presentation of information received from a plurality of medical devices in a health care network is provided. Information that is received from the medical device may be decoded by the system into metrics based on values extracted from the medical device. The system may then model the decoded information and/or metrics into a format which is useful for an end user. Additionally, the system may then have a presentation model which allows the information to be presented to the end user via a preferred display mechanism. In an embodiment, the mechanism may be a chart, graph or text readout. The system may have a sensor incorporated which produces the metric and decodes the raw data received from the medical devices. The system may also include a controller which may view all data received from the medical devices and analyzes for changes.
In this pilot study, 15 patients age 18-75 with multiple myeloma will be admitted to the hospital and treated with a single dose of high dose melphalan. Stem cell infusion will occur per institutional standard of care. Patients will then receive plinabulin 40mg flat dose IV infusion, infused over approximately 30 minutes starting between 1-3 hours after stem cell infusion on day 0. Pegfilgrastim 6mg will be administered as per standard of care on day +1.
HIV-1 infected children participants (aged less than \[\<\] 12 years) will continue to receive darunavir (DRV) 200 to 600 milligrams (mg) as oral suspension twice daily (BID) along with ritonavir (rtv) 32 to 100 mg as oral solution/suspension BID. HIV-1 infected adolescent participants (aged 12-17 years) will continue to receive DRV 200 to 600 mg as oral suspension BID along with rtv 32 to 100 mg as oral solution/suspension BID. Dosing for children and adolescent participants will be based on body weight (per parent study TMC114-TiDP29-C232). HIV-1 infected adult participants (aged greater than or equal to \[\>=\] 18 years) will continue to receive DRV 800 mg (2 tablets of 400 mg) orally every day (qd) along with rtv 100 mg tablet (per parent study TMC114-C211) or DRV 600 mg tablet orally BID along with rtv 100 mg tablet (per parent study TMC114-C214 or TMC114-TiDP31-C229).
The primary objective of this study is to evaluate the effect of a single nutrient dietary supplement on dynamic stability in an older population. Dynamic stability, or walking stability, will be assessed with accelerometers while subjects are walking on a flat surface for about 60 seconds. Dynamic stability will be defined by the maximum Lyapunov exponent (maxLE), Floquet multiplier, or motor control timing, change from baseline. Postural stability will also be measured in a still and standing subject, with foot placement standardized on a force plate, and with the subject looking in the forward direction with arms by their sides. Two visual conditions will be given: eyes-open (EO) and eyes-closed (EC). Each measurement will last for 60 seconds and will be repeated twice for each condition. A three-minute rest will be provided between measurements.
The present invention provides a medicine for curing diabetic peripheral neuropathy, and a preparation method thereof. In the present invention, the cause and the pathogenesis of diabetic peripheral neuropathy are studied by applying traditional Chinese medicine meridian disease theories. The medicine has the effect of restoring the normal function of the meridian, activating the meridian for stopping pain, benefiting vital energy and nourishing yin by performing the main functions of dredging the meridian by invigorating vital energy and nourishing and moistening the meridian and matching the methods of promoting blood circulation for dredging the meridian, resolving tetany and dredging the meridian by extinguishing wind, dredging the meridian by eliminating pathogens and expelling wind, and dissipating cold and dredging the meridian by eating spicy and warm food on the basis of the pathology of the deficiency of both vital energy and yin. Thereby, the present invention makes treatment rules according to the mechanisms. The present invention takes astragalus root as a principal medicine, takes rehmannia root, suberect spatholobus and chuanxiong rhizome as minister medicines, and takes angelica, common anemarrhena rhizome, earth worm, mulberry twig, paniculate swallowwort root, lychee seed, rhizoma corydalis, cassia twig and ephedrae as adjuvant medicines. The medicine treats both the manifestations and the root causes of diseases, and promotes the rehabilitation of diseases. Experimental research indicates that medicine of the present invention has significant effect of improving some peripheral nerve complications of diabetics, such as acroparesthesia, numb limbs, painful limbs, etc.
Participants who meet the inclusion and exclusion criteria will undergo postural control assessment with the Biodex Balance System® and hand-eye coordination test with the Alternate Hand Wall Toss Test. Subjects will be given 65 ml of Turkish coffee (one cup) to ensure oral caffeine intake. The same assessments will be repeated 30 minutes after caffeine intake.
The BTS-C is an online sleep health education program that is located on a mobile application. The BTS-C utilizes asynchronous avatar-based interactive learning and educational content and videos that are tailored to the caregivers' goals and expectations, paired with targeting messages for change surrounding principles of sleep health practices. The modules will be completed over the course of 6 weeks.
PURPOSE: A pharmaceutical composition containing Dendropanax morbifera Lev. extract is provided to prevent or treat liver diseases and to remarkably suppress liver cancer cells without side effect. CONSTITUTION: A pharmaceutical composition for preventing and treating liver diseases contains Dendropanax morbifera Lev. branch or leaf extract. A method for preparing the extract comprises: a step of cutting Dendropanax morbifera Lev. branches or leaves and extracting in ethanol at 95-100 Deg. C. for 24-72 hours; a step of filtering the extract to prepare a primary filtered liquid; a step of cooling the primary filtered liquid at 40-60 Deg. C. and filtering to prepare a secondary filtered liquid; a step of concentrating the secondary filtered liquid to prepare a concentrate; a step of suspending the concentrate in water and fractioning with hexane, ethyl acetate, and butanol to prepare a hexane, ethyl acetate, and butanol fraction; and a step of dissolving the hexane, ethyl acetate, or butanol fraction with methanol.
The present invention relates to medicine liquid for burns with quick healing and without scars and a preparation method thereof. The medicine liquid for burns is used for treating various burns and scalds, which is a pure Chinese herbal preparation of the hereditary secret formula, without sterilizing wound surfaces; no scars are left after the wound surfaces are healed. Bamboo rice (1), ternate grape fern herb (2), smallflower galinsoga herb (3), tuckahoe (4), common cyanotis root flower (5), salamander (6), antler (7) and brassicae chinensis (8) are respectively distilled, boiled, crushed and sieved and carry out the aging treatment to be prepared into the medicine liquid for burns. The course of treatment is shortened by more than 1/2, and the cost is low. The medicine liquid for burns has very good effect on electrical burns of ten thousand of high tension electricity, cutter wounds, gunshot wounds and deep burns with large areas. By the clinical verification of thousands of cases, the total effective rate reaches by 100%, and the cure rate reaches by 100%. The medicine liquid for burns is necessary good medicine for families and field work.
ORBACTIV is administered intravenously. ORBACTIV should only be diluted in D5W. Do NOT use sodium chloride injection for dilution as it is incompatible with ORBACTIV and may cause precipitation of the drug. Therefore other intravenous substances, additives or other medications mixed in sodium chloride injection should not be added to ORBACTIV single-dose vials or infused simultaneously through the same IV line or through a common intravenous port.

In addition, drugs formulated at a basic or neutral pH may be incompatible with ORBACTIV. ORBACTIV should not be administered simultaneously with commonly used intravenous drugs through a common intravenous port. If the same intravenous line is used for sequential infusion of additional medications, the line should be flushed before and after infusion of ORBACTIV with D5W.